The Unique Characteristics of Tumor Vasculature and Preclinical Evidence for its Selective Disruption by Tumor-Vascular Disrupting Agents

Por Siemann, Dietmar W.
Publicado em 2010

Dual Targeting of Tumor Vasculature: Combining Avastin and Vascular Disrupting Agents (CA4P or OXi4503)

Por Siemann, Dietmar W., Shi, Wenyin
Publicado em 2008

Inhibition of endothelial/smooth muscle cell contact loss by the investigational Angiopoietin-2 antibody MEDI3617

Por Molnar, Nikolett, Siemann, Dietmar W.
Publicado em 2012

Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607

Por Dai, Yao, Siemann, Dietmar W
Publicado em 2012

Characterizing the Tumor Response to CA4P Treatment

Por Salmon, Beth A., Siemann, Dietmar W.
Publicado em 2007

Vascular targeted therapies in oncology

Por Siemann, Dietmar W., Horsman, Michael R.
Publicado em 2008

Temporal Aspects of the Action of ASA404 (Vadimezan; DMXAA)

Por Baguley, Bruce C, Siemann, Dietmar W
Publicado em 2010

Cathepsin L Inhibition by the Small Molecule KGP94 Suppresses Tumor Microenvironment Enhanced Metastasis Associated Cell Functions of Prostate and Breast Cancer Cells

Por Sudhan, Dhivya R., Siemann, Dietmar W.
Publicado em 2013

Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference

Por Biel, Nikolett M., Siemann, Dietmar W.
Publicado no Cancer Lett (2014)

Modulation of the Tumor Vasculature and Oxygenation to Improve Therapy

Por Siemann, Dietmar W., Horsman, Michael R.
Publicado no Pharmacol Ther (2015)

Cathepsin L targeting in cancer treatment

Por Sudhan, Dhivya R., Siemann, Dietmar W.
Publicado no Pharmacol Ther (2015)

IMPACT OF HYPOXIA ON THE METASTATIC POTENTIAL OF HUMAN PROSTATE CANCER CELLS

Por DAI, YAO, BAE, KYUNGMI, SIEMANN, DIETMAR W.
Publicado em 2011

Another road leads to HIF-1 activation: implications for prostate cancer progression

Por Dai, Yao, Bae, Kyungmi, Siemann, Dietmar W
Publicado em 2012

THE VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 TYROSINE KINASE INHIBITOR CEDIRANIB (RECENTIN; AZD2171) INHIBITS ENDOTHELIAL CELL FUNCTION AND GROWTH OF HUMAN RENAL TUMOR XENOGRA...

Por Siemann, Dietmar W., Brazelle, W. D., Jürgensmeier, Juliane M.
Publicado em 2009

In vivo functional differences in microvascular response of 4T1 and Caki-1 tumors after treatment with OXi4503

Por WANKHEDE, MAMTA, DEDEUGD, CASEY, SIEMANN, DIETMAR W., SORG, BRIAN S.
Publicado em 2010

Monitoring the Treatment Efficacy of the Vascular Disrupting Agent CA4P

Por Salmon, Beth A., Salmon, Howard W., Siemann, Dietmar W.
Publicado em 2007

Src Signaling Interference Impairs the Dissemination of Blood-Borne Tumor Cells

Por Siemann, Dietmar W., Dong, Meiyu, Pampo, Chris, Shi, Wenyin
Publicado em 2012

A REVIEW AND UPDATE OF THE CURRENT STATUS OF THE VASCULATURE DISABLING AGENT COMBRETASTATIN-A4 PHOSPHATE (CA4P)

Por Siemann, Dietmar W., Chaplin, David J., Walicke, Patricia A.
Publicado em 2009

Impact of Tumor Cell VEGF Expression on the In Vivo Efficacy of Vandetanib (ZACTIMA(™); ZD6474)

Por SIEMANN, DIETMAR W., NORRIS, CHRISTINA M., RYAN, ANDERSON, SHI, WENYIN
Publicado em 2009

Cathepsin L inactivation leads to multimodal inhibition of prostate cancer cell dissemination in a preclinical bone metastasis model

Por Sudhan, Dhivya R., Pampo, Christine, Rice, Lori, Siemann, Dietmar W.
Publicado no Int J Cancer (2016)